Cellectar Biosciences (CLRB) has issued an update.
At a recent company meeting, stockholders voted on four key proposals, leading to the election of directors Asher Chanan-Khan and John Neis for three-year terms, approval of a 7 million share increase in the Stock Incentive Plan, ratification of Baker Tilly US, LLP as the independent auditor for 2024, and endorsement of executive compensation in an advisory capacity. Each proposal received strong majority support, reflecting stockholder confidence in the company’s leadership and strategic incentives.
See more data about CLRB stock on TipRanks’ Stock Analysis page.
